Weight

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with type 2 diabetes

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off the drugs

The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works

A plethora of new weight-loss drugs are now available in the U.S., but they aren’t necessarily the same. Here’s a guide to the latest GLP-1 receptor agonists

Popular weight-loss and diabetes drugs, such as Ozempic and Wegovy, target metabolic pathways that gut microbes and food molecules already play a key role in regulating

The world has launched into an era of injectables not just to treat obesity but to manage weight. Is that all good news?

Studies of goal setting reveal why it’s so hard to keep resolutions—and how to make ones that actually stick

Ozempic and similar drugs are ushering in a new era of weight management and obesity treatments, and researchers are racing to understand their impact

From new uses for weight-loss drugs to the first CRISPR gene editing therapy, these were some of the most impactful health stories of the year

The active ingredient in Wegovy and Ozempic reduced the risk of heart attacks and strokes in a large trial of people with cardiovascular disease who were considered overweight or had obesity, but the cost and side effects remain barriers

Laxative misuse is cropping up in wellness and weight-loss social media communities—and some experts are concerned about its close ties to eating disorders

Recent studies evaluate risks associated with drugs such as Wegovy and Mounjaro